CMPS

COMPASS Pathways is a biotechnology company developing a new psychiatric treatment based on psilocybin, the active ingredient in certain mushrooms. They are testing this treatment, called COMP360, in clinical trials to see if it can help people with treatment-resistant depression (depression that does not respond to standard medications), as well as post-traumatic stress disorder and anorexia nervosa. The company is based in London and operates in both the United Kingdom and the United States.